| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5502444 | Journal of Geriatric Oncology | 2016 | 7 Pages |
Abstract
This review gives an overview of the benefits and toxicities of the currently available treatments in very elderly MM patients with a focus on first-line treatment. In addition we discuss the role of geriatric assessment to optimize treatment efficacy in the more vulnerable cohort.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Ageing
Authors
Nicolas Kint, Michel Delforge,